MX2023000521A - Derivados de piridazinil-amino como inhibidores de el receptor tipo i de factor de crecimiento transformante beta (alk5). - Google Patents

Derivados de piridazinil-amino como inhibidores de el receptor tipo i de factor de crecimiento transformante beta (alk5).

Info

Publication number
MX2023000521A
MX2023000521A MX2023000521A MX2023000521A MX2023000521A MX 2023000521 A MX2023000521 A MX 2023000521A MX 2023000521 A MX2023000521 A MX 2023000521A MX 2023000521 A MX2023000521 A MX 2023000521A MX 2023000521 A MX2023000521 A MX 2023000521A
Authority
MX
Mexico
Prior art keywords
amino derivatives
alk5
alk5 inhibitors
compounds
pyridazinyl amino
Prior art date
Application number
MX2023000521A
Other languages
English (en)
Inventor
Matteo Biagetti
Barbara Bertani
Paolo Ronchi
Paolo Bruno
Daniela Pizzirani
Daniele Pala
Sara Guariento
Alessio Barilli
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MX2023000521A publication Critical patent/MX2023000521A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a un compuesto de la fórmula general (I) que inhibe el receptor tipo I de factor de crecimiento transformante-ß (TGF-ß) (ALK5), métodos para preparar estos compuestos, composiciones farmacéuticas que los contienen y uso terapéutico de los mismos. Los compuestos de la invención pueden ser útiles en el tratamiento de enfermedades o condiciones asociadas con una desregulación de la ruta de señalización de ALK5 en un mamífero.
MX2023000521A 2020-07-15 2021-07-14 Derivados de piridazinil-amino como inhibidores de el receptor tipo i de factor de crecimiento transformante beta (alk5). MX2023000521A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20185890 2020-07-15
PCT/EP2021/069649 WO2022013307A1 (en) 2020-07-15 2021-07-14 Pyridazinyl amino derivatives as alk5 inhibitors

Publications (1)

Publication Number Publication Date
MX2023000521A true MX2023000521A (es) 2023-02-13

Family

ID=71620257

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000521A MX2023000521A (es) 2020-07-15 2021-07-14 Derivados de piridazinil-amino como inhibidores de el receptor tipo i de factor de crecimiento transformante beta (alk5).

Country Status (12)

Country Link
US (1) US20240018122A1 (es)
EP (1) EP4182308A1 (es)
JP (1) JP2023533849A (es)
KR (1) KR20230051500A (es)
CN (1) CN116096719A (es)
AR (1) AR122986A1 (es)
AU (1) AU2021307559A1 (es)
BR (1) BR112023000588A8 (es)
CA (1) CA3184990A1 (es)
MX (1) MX2023000521A (es)
TW (1) TW202216677A (es)
WO (1) WO2022013307A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023043050A (ja) * 2021-09-15 2023-03-28 株式会社東芝 新規アミン化合物、酸性ガス吸収剤、酸性ガスの除去方法及び酸性ガス除去
CN114957331A (zh) * 2022-04-22 2022-08-30 北京康辰药业股份有限公司 磷酸酯取代的环丙酰胺衍生喹唑啉类化合物的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002541253A (ja) 1999-04-09 2002-12-03 スミスクライン・ビーチャム・コーポレイション トリアリールイミダゾール
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
CA2422367C (en) 2000-09-15 2010-05-18 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP2004523474A (ja) 2000-09-20 2004-08-05 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド チロシンキナーゼモジュレーターとしてのピラジン誘導体
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
AU2004278382B2 (en) 2003-09-30 2008-09-18 Amgen Inc. Vanilloid receptor ligands and their use in treatments
AU2007271964B2 (en) 2006-07-14 2012-01-19 Novartis Ag Pyrimidine derivatives as ALK-5 inhibitors
ATE522249T1 (de) 2007-07-26 2011-09-15 Novartis Ag Organische verbindungen
US8367662B2 (en) 2007-10-17 2013-02-05 Novartis Ag Organic compounds
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
US8343966B2 (en) 2008-01-11 2013-01-01 Novartis Ag Organic compounds
KR20100113557A (ko) 2008-01-11 2010-10-21 노파르티스 아게 키나제 억제제로서의 피리미딘
PL2307402T3 (pl) 2008-04-29 2013-05-31 Novartis Ag Pochodne imidazo-pirydyny jako inhibitory kinazy podobnej do receptora aktywiny (ALK4 lub ALK5)
KR101938368B1 (ko) 2011-07-13 2019-01-14 주식회사 티움바이오 Alk5 및/또는 alk4 억제제로서의 2-피리딜-치환된 이미다졸
WO2020012357A1 (en) * 2018-07-10 2020-01-16 Integral Biosciences Pvt. Ltd. Heterocyclic compounds and methods of use

Also Published As

Publication number Publication date
AU2021307559A1 (en) 2023-02-16
AR122986A1 (es) 2022-10-19
CN116096719A (zh) 2023-05-09
KR20230051500A (ko) 2023-04-18
TW202216677A (zh) 2022-05-01
BR112023000588A8 (pt) 2023-05-09
US20240018122A1 (en) 2024-01-18
EP4182308A1 (en) 2023-05-24
BR112023000588A2 (pt) 2023-01-31
WO2022013307A1 (en) 2022-01-20
CA3184990A1 (en) 2022-01-20
JP2023533849A (ja) 2023-08-04

Similar Documents

Publication Publication Date Title
CR20230310A (es) Inhibidores de prmt5
MX2022010011A (es) Inhibidores de prmt5 novedosos.
GEP20156285B (en) Compounds and compositions as trk inhibitors
EA201100391A1 (ru) Соединения, ингибирующие активность семикарбазид-чувствительной аминооксидазы
ATE517882T1 (de) Chinolinderivate
NO20033181L (no) Substituerte alkylaminderivater og fremgangsmåter for anvendelse
TW200616979A (en) Non-nucleoside reverse transcriptase inhibitors
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
MX2023000521A (es) Derivados de piridazinil-amino como inhibidores de el receptor tipo i de factor de crecimiento transformante beta (alk5).
TW200639159A (en) Treatment of pain
DE602008001725D1 (de) 1-(1-benzylpiperidin-4-yl)benzimidazol-5-carbonsäurederivate zur behandlung von diabetes mellitus
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
GEP20135806B (en) Lactams as beta secretase inhibitors
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
TW200716547A (en) Piperidin-4-yl-amide derivatives
PH12021550554A1 (en) N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
DE602007001463D1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate
MX2022013273A (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus metodos de uso.
UA106082C2 (uk) АМІНОПІРАЗОЛ ТРИАЗОЛОТІАДІАЗОЛЬНІ ІНГІБІТОРИ ПРОТЕЇНКІНАЗИ c-МЕТ
MY153733A (en) Novel quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same
MX2023000519A (es) Derivados de pirido-oxazina-amino como inhibidores de alk5.
MX2023011057A (es) Derivados de indolina como inhibidores de receptores de dominio de discoidina 1 (ddr1) y receptores de dominio de discoidina 2 (ddr2).